PR Newswire Clinical TrialsOriginal article
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
Phase 2positivedabogratinibPositive
AI Analysis
Summary
Tyra Biosciences reported positive Phase 2 SURF302 results for dabogratinib, demonstrating favorable safety and tolerability supporting potential chronic dosing as a first-line oral treatment for low-grade intermediate-risk non-muscle-invasive bladder cancer.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Favorable safety and tolerability results supporting chronic dosing potential with no clinically significant hyperphosphatemia, nail toxicity or ocular toxicity, and low frequency of adverse events
Importance:6/10
Sentiment:
0.75
Phase 2 dataoral therapyNMIBCsafety profiledabogratinib
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 9, 2026 11:00 AM